Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 18/20 | 0.74 |
| ▸ | CDK9 | P50750 | 18/20 | 0.74 |
| ▸ | CDK7 | P50613 | 14/20 | 0.74 |
| ▸ | CCNH | P51946 | 13/20 | 0.74 |
| ▸ | MNAT1 | P51948 | 12/20 | 0.74 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.68 |
| ▸ | CDK2 | P24941 | 14/20 | 0.68 |
| ▸ | CCNK | O75909 | 15/20 | 0.60 |
| ▸ | CDK12 | Q9NYV4 | 15/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655161 | 1.00 | CCNT1 (0.74) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL30440015 | 1.00 | CCNT1 (0.74) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL29394684 | 1.00 | CCNT1 (0.74) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL30886754 | 1.00 | CCNT1 (0.74) | CCNT1CDK9CDK7CCNHMNAT1 | |
| Hydrochloric Acid SCHEMBL31006806 | 0.99 | CCNT1 (0.73) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16655092 | 0.95 | CCNT1 (0.66) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16665576 | 0.95 | CCNT1 (0.66) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16655089 | 0.95 | CCNT1 (0.66) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL29994336 | 0.90 | CCNT1 (0.59) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL16655358 | 0.90 | CCNT1 (0.59) | CCNT1CDK9CDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574255-B | Organic arsine-based CDK inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-05-10 | — | — | CN | disclosed |
| US-20220227734-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| CN-113993519-A | Degradation agent for cyclin dependent kinase 12(CDK12) and use thereof | 达纳-法伯癌症研究公司 | 2022-01-28 | — | — | CN | disclosed |
| US-11040957-B2 | Heteroaromatic compounds useful for the treatment of proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021057867-A1 | CLASS OF CDK INHIBITOR BASED ON ORGANIC ARSINE, PREPARATION METHOD AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574255-A | Organic arsine-based CDK inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020219650-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219650-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20190241541-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-08-08 | — | — | US | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| EP-3057955-B1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| EP-3126352-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015058126-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241541-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK4 | CCNT1 33/4885CDK9 6/4885CDK7 1/4885 |
| US-11040957-B2 | Heteroaromatic compounds useful for the treatment of proliferative diseases | CDK7, CDK3, CDK4 | CCNT1 33/4885CDK9 6/4885CDK7 1/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNT1 34/4885CDK9 3/4885CDK7 1/4885 |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CCNT1 35/4885CDK9 5/4885CDK7 1/4885 |
| US-20220227734-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK2 | CCNT1 67/4885CDK9 9/4885CDK7 31/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNT1 34/4885CDK9 3/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.